AI ASSISTANT
Ask DrugCentral
Explore drug properties, targets, and indications with answers grounded in DrugCentral.
Powered by DrugCentral + retrieval-augmented AIYour question
Ask in your own words. Each question is answered independently.
Explore sample questions
Select a question to fill the editor, then ask it or make it your own.
DrugCentral answer
Your answer will appear here. Open linked drug cards in a new tab to explore the source details.
About Ask DrugCentral
Ask DrugCentral helps you explore drug properties, biological targets, and indications using natural language. Sample questions offer starting points, and linked drug cards let you check the underlying records.
General architecture
- Ask a questionThe browser sends your question to the same-origin Django chat API.
- Retrieve and generateThe API forwards the question to the configured DrugCentral retrieval-augmented generation (RAG) service, which returns an AI-generated answer.
- Explore the answerThe app resolves cited drug-card names and displays the answer with links to drug records.
Using the assistant
Each request is independent; previous questions are not sent as conversation history. You can edit a sample before submitting, retry a failed request, or switch back to normal search. Drug links open in a new tab so your question and answer stay available.
Answers may contain mistakes or omit information. Verify details against DrugCentral records and original sources.
AI can make mistakes. Verify answers against the original sources before relying on them.
silicon dioxide 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |
| Stem definition | Drug id | CAS RN |
|---|---|---|
| 4284 | 7631-86-9 |
Description:
| Molecule | Description |
|---|---|
|
Synonyms:
|
A non-crystalline form of silicon oxide that has absorptive properties. It is commonly used as a desiccating agent and as a stationary phase for CHROMATOGRAPHY. The fully hydrated form of silica gel has distinct properties and is referred to as SILICIC ACID.
|
Drug dosage:
None
ADMET properties:
None
Predicted pharmacokinetic/toxicological properties (PK-AZ):
| Property | Description | Value | Unit | Confidence | Similarity |
|---|---|---|---|---|---|
| kinase-safety-class | ACVR2A,ACVR2B,ACVRL1,AKT3,ALK,AURKA,AURKC,AXL,BRAF,BTK,CAMK2B,CAMK2D,CDK1,CDK4,CDK5,CDK9,CSF1R,DDR1,DYRK1B,EGFR,EIF2AK3,EPHB4,ERBB2,FLT3,GRK2,GRK3,GSK3B,IKBKB,IRAK1,ITK,JAK1,JAK2,KDR,MAP2K6,MAP3K14,MAP3K21,MAP3K7,MAP4K1,MAP4K3,MAPK10,MAPK12,MAPK7,MAPK9,MAPKAPK2,MARK4,MET,MTOR,NTRK1,NTRK2,PDK1,PDK2,PDK4,PIK3CB,PIK3CD,PIM2,PLK1,PRKCD,PRKDC,SIK2,SIK3,STK33,SYK,TEK,TGFBR1,TTK,ULK1,ULK2,ZAP70 | 68 | |||
| kinase-selectivity-class | BMX,CDK9,DYRK1B,GRK2,GSK3B,HIPK2,MAP2K6,MAP3K14,MAPK7,PIK3CG,PRKDC,STK33 | 12 | |||
| pfas-class | PFAS structural alert (1 = True, 0 = False) | 0 |
Approvals:
| Date | Agency | Company | Orphan |
|---|---|---|---|
| None | FDA |
FDA Adverse Event Reporting System (Female)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Febrile neutropenia | 112.65 | 18.09 | 72 | 3409 | 158277 | 90466689 |
| Hepatic function abnormal | 68.26 | 18.09 | 34 | 3447 | 46254 | 90578712 |
| Neutrophil count decreased | 51.91 | 18.09 | 33 | 3448 | 71499 | 90553467 |
| Platelet count decreased | 50.71 | 18.09 | 42 | 3439 | 136927 | 90488039 |
| Myelosuppression | 47.24 | 18.09 | 28 | 3453 | 53563 | 90571403 |
| Exposure to toxic agent | 36.07 | 18.09 | 13 | 3468 | 7954 | 90617012 |
| Death | 35.41 | 18.09 | 63 | 3418 | 456488 | 90168478 |
| Skin lesion | 31.56 | 18.09 | 19 | 3462 | 37346 | 90587620 |
| Acute myeloid leukaemia | 24.18 | 18.09 | 13 | 3468 | 20627 | 90604339 |
| Laryngeal inflammation | 22.43 | 18.09 | 4 | 3477 | 137 | 90624829 |
| Atrioventricular conduction time shortened | 21.27 | 18.09 | 3 | 3478 | 21 | 90624945 |
| White blood cell count decreased | 21.23 | 18.09 | 29 | 3452 | 167080 | 90457886 |
| Blood electrolytes increased | 20.13 | 18.09 | 3 | 3478 | 32 | 90624934 |
| Rectal lesion | 18.67 | 18.09 | 3 | 3478 | 54 | 90624912 |
| Liver disorder | 18.44 | 18.09 | 23 | 3458 | 121246 | 90503720 |
FDA Adverse Event Reporting System (Male)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Febrile neutropenia | 101.63 | 26.36 | 79 | 2021 | 185624 | 42433611 |
| Myelosuppression | 67.55 | 26.36 | 35 | 2065 | 40426 | 42578809 |
| Hepatic function abnormal | 56.97 | 26.36 | 34 | 2066 | 51533 | 42567702 |
| Platelet count decreased | 39.60 | 26.36 | 41 | 2059 | 138540 | 42480695 |
| Visual evoked potentials abnormal | 38.70 | 26.36 | 6 | 2094 | 65 | 42619170 |
| CADASIL | 36.35 | 26.36 | 6 | 2094 | 99 | 42619136 |
| Magnetic resonance imaging spinal abnormal | 34.37 | 26.36 | 6 | 2094 | 140 | 42619095 |
| Saccadic eye movement | 33.57 | 26.36 | 6 | 2094 | 161 | 42619074 |
| Double stranded DNA antibody positive | 32.17 | 26.36 | 6 | 2094 | 205 | 42619030 |
| Cerebral microangiopathy | 31.89 | 26.36 | 6 | 2094 | 215 | 42619020 |
| Central nervous system inflammation | 31.68 | 26.36 | 6 | 2094 | 223 | 42619012 |
| Acute myeloid leukaemia | 30.75 | 26.36 | 17 | 2083 | 22239 | 42596996 |
| Physical examination abnormal | 27.49 | 26.36 | 6 | 2094 | 455 | 42618780 |
| Creatinine renal clearance increased | 27.38 | 26.36 | 6 | 2094 | 464 | 42618771 |
| Lipid metabolism disorder | 27.04 | 26.36 | 6 | 2094 | 491 | 42618744 |
FDA Adverse Event Reporting System (Geriatric)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Febrile neutropenia | 224.67 | 18.39 | 149 | 4550 | 316618 | 110267982 |
| Hepatic function abnormal | 132.49 | 18.39 | 68 | 4631 | 89227 | 110495373 |
| Myelosuppression | 114.93 | 18.39 | 63 | 4636 | 94277 | 110490323 |
| Platelet count decreased | 90.00 | 18.39 | 76 | 4623 | 230367 | 110354233 |
| Neutrophil count decreased | 64.59 | 18.39 | 48 | 4651 | 120893 | 110463707 |
| Exposure to toxic agent | 59.90 | 18.39 | 22 | 4677 | 12836 | 110571764 |
| Death | 57.92 | 18.39 | 105 | 4594 | 698764 | 109885836 |
| Acute myeloid leukaemia | 56.37 | 18.39 | 29 | 4670 | 38081 | 110546519 |
| Pneumonia | 43.67 | 18.39 | 107 | 4592 | 876607 | 109707993 |
| Liver disorder | 36.19 | 18.39 | 37 | 4662 | 142206 | 110442394 |
| Renal disorder | 29.47 | 18.39 | 21 | 4678 | 49458 | 110535142 |
| Bone marrow failure | 26.54 | 18.39 | 21 | 4678 | 57827 | 110526773 |
| White blood cell count decreased | 26.32 | 18.39 | 40 | 4659 | 229350 | 110355250 |
| Bronchopulmonary aspergillosis | 25.84 | 18.39 | 16 | 4683 | 29847 | 110554753 |
| Electrocardiogram QT prolonged | 23.54 | 18.39 | 26 | 4673 | 108934 | 110475666 |
| Anaemia | 21.25 | 18.39 | 61 | 4638 | 547025 | 110037575 |
| Pneumonia fungal | 21.15 | 18.39 | 11 | 4688 | 14743 | 110569857 |
| Atrioventricular conduction time shortened | 20.96 | 18.39 | 3 | 4696 | 21 | 110584579 |
| Blast cell count increased | 20.82 | 18.39 | 6 | 4693 | 1631 | 110582969 |
| Sepsis | 20.68 | 18.39 | 44 | 4655 | 327302 | 110257298 |
| Pyrexia | 19.86 | 18.39 | 83 | 4616 | 898182 | 109686418 |
| Laryngeal inflammation | 18.55 | 18.39 | 4 | 4695 | 333 | 110584267 |
FDA Adverse Event Reporting System (Pediatric)
None
Pharmacologic Action:
| Source | Code | Description |
|---|---|---|
| MeSH PA | D058427 | Hygroscopic Agents |
Drug Use | Suggest Off label Use Form| |View source of the data|
| Disease | Relation | SNOMED_ID | DOID |
|---|---|---|---|
| Peptic ulcer | indication | 13200003 | DOID:750 |
| Heartburn | indication | 16331000 | |
| Indigestion | indication | 162031009 | |
| Gastroesophageal reflux disease | indication | 235595009 | DOID:8534 |
| Flatulence symptom | indication | 308698004 | |
| Gastric Hypersecretory Conditions | indication | ||
| Hiatal Hernia with Reflux Esophagitis | indication | ||
| Gastrointestinal Radiography Adjunct | indication | ||
| Multiple endocrine adenomas | off-label use | 60549007 | |
| Systemic mast cell disease | off-label use | 397016004 | DOID:349 |
| Stress-Related GI Mucosal Bleeding Prevention | off-label use | ||
| Hypophosphatemia | contraindication | 4996001 | |
| Constipation | contraindication | 14760008 | DOID:2089 |
| Fecal impaction | contraindication | 44635007 | |
| Chronic heart failure | contraindication | 48447003 | |
| Acute nephropathy | contraindication | 58574008 | |
| Diarrhea | contraindication | 62315008 | |
| Hemorrhoids | contraindication | 70153002 | DOID:9746 |
| Oliguria | contraindication | 83128009 | |
| Kidney disease | contraindication | 90708001 | DOID:557 |
| Gastrointestinal obstruction | contraindication | 126765001 | |
| Chronic diarrhea | contraindication | 236071009 | |
| Aluminum intoxication | contraindication | 236546003 | |
| Edema | contraindication | 267038008 |
🐶 Veterinary Drug Use
None
🐶 Veterinary products
None
Acid dissociation constants calculated using MoKa v3.0.0
None
Orange Book patent data (new drug applications)
None
Orange Book exclusivity data (new drug applications)
None
Bioactivity Summary:
None
External reference:
| ID | Source |
|---|---|
| 4024439 | VUID |
| N0000158434 | NUI |
| 4010521 | VANDF |
| 4020878 | VANDF |
| 4024439 | VANDF |
| C0037098 | UMLSCUI |
| CHEBI:30563 | CHEBI |
| CHEMBL2108563 | ChEMBL_ID |
| D012822 | MESH_DESCRIPTOR_UI |
| DB11132 | DRUGBANK_ID |
| ETJ7Z6XBU4 | UNII |
| 24261 | PUBCHEM_CID |
| 9771 | RXNORM |
| NOCODE | MMSL |
| 005872 | NDDF |
| D058428 | MESH_DESCRIPTOR_UI |
| ETJ7Z6XBU4 | INXIGHT DRUGS |
Pharmaceutical products:
| Product | Category | Ingredients | NDC | Form | Quantity | Route | Marketing | Label |
|---|---|---|---|---|---|---|---|---|
| E-Z-GASII | HUMAN OTC DRUG LABEL | 4 | 10361-793 | GRANULE, EFFERVESCENT | 10 mg | ORAL | OTC Monograph Drug | 11 sections |
| NANO SILVER TOOTHPASTE | HUMAN OTC DRUG LABEL | 3 | 45163-451 | PASTE | 14 g | ORAL | OTC monograph final | 5 sections |
| Type 3 Sinus Max | HUMAN OTC DRUG LABEL | 4 | 50169-0005 | TABLET, ORALLY DISINTEGRATING | 200 [hp_C] | ORAL | unapproved drug other | 9 sections |
| BAMBOO SALT Eunganggo Jook Yeom Toothpaste | HUMAN OTC DRUG LABEL | 7 | 53208-459 | PASTE | 20 g | DENTAL | OTC monograph not final | 4 sections |
| BAMBOO SALT Eunganggo Jook Yeom | HUMAN OTC DRUG LABEL | 7 | 53208-505 | PASTE | 20 g | DENTAL | OTC monograph not final | 8 sections |
| Simethicone | HUMAN OTC DRUG LABEL | 2 | 54868-5620 | SOLUTION/ DROPS | 3.70 mg | ORAL | OTC MONOGRAPH FINAL | 8 sections |
| 10 Parasite Detox | HUMAN OTC DRUG LABEL | 15 | 55146-010 | LIQUID | 30 [hp_C] | ORAL | unapproved homeopathic | 9 sections |
| CS Bone | HUMAN OTC DRUG LABEL | 11 | 57955-0211 | LIQUID | 10 [hp_X] | ORAL | unapproved homeopathic | 9 sections |
| PediaCare Gas Relief Drops Dye Free | HUMAN OTC DRUG LABEL | 2 | 63029-811 | LIQUID | 0.01 g | ORAL | OTC MONOGRAPH FINAL | 11 sections |
| Gelusil | HUMAN OTC DRUG LABEL | 4 | 65197-300 | TABLET, CHEWABLE | 1 mg | ORAL | OTC Monograph Drug | 13 sections |
| 2080 Dentistry Night Fresh | HUMAN OTC DRUG LABEL | 1 | 67225-0009 | PASTE, DENTIFRICE | 15 g | DENTAL | OTC monograph final | 13 sections |
| 2080 Dentistry Night Repair | HUMAN OTC DRUG LABEL | 1 | 67225-0010 | PASTE, DENTIFRICE | 15 g | DENTAL | OTC monograph final | 13 sections |
| EVERTOX SPECIAL BATH PREPARATIONS | HUMAN OTC DRUG LABEL | 1 | 69474-1001 | POWDER | 20 g | TOPICAL | unapproved drug other | 7 sections |
| Finefra Tooth | HUMAN OTC DRUG LABEL | 2 | 69653-050 | PASTE, DENTIFRICE | 15 g | TOPICAL | unapproved drug other | 8 sections |
| Finefra Black Tooth | HUMAN OTC DRUG LABEL | 2 | 69653-100 | PASTE, DENTIFRICE | 15 g | TOPICAL | unapproved drug other | 8 sections |
| Finefra Black Tooth | HUMAN OTC DRUG LABEL | 2 | 69653-110 | PASTE, DENTIFRICE | 20.25 g | TOPICAL | unapproved drug other | 8 sections |
| Finefra Kids Tooth | HUMAN OTC DRUG LABEL | 2 | 69653-120 | PASTE, DENTIFRICE | 9.10 g | TOPICAL | unapproved drug other | 8 sections |
| Alegria Neo | HUMAN OTC DRUG LABEL | 2 | 70406-020 | PASTE, DENTIFRICE | 2.80 g | TOPICAL | unapproved drug other | 8 sections |
| Olea Olidental | HUMAN OTC DRUG LABEL | 1 | 70417-002 | PASTE | 170 mg | ORAL | unapproved drug other | 8 sections |
| Exoden Cavity | HUMAN OTC DRUG LABEL | 3 | 70602-005 | PASTE | 15 g | TOPICAL | unapproved drug other | 8 sections |
| Exoden Sensitive | HUMAN OTC DRUG LABEL | 2 | 70602-006 | PASTE | 2.50 g | TOPICAL | unapproved drug other | 8 sections |
| Exoden Gum | HUMAN OTC DRUG LABEL | 2 | 70602-007 | PASTE | 15 g | TOPICAL | unapproved drug other | 8 sections |
| Exoden White | HUMAN OTC DRUG LABEL | 2 | 70602-008 | PASTE | 15 g | TOPICAL | unapproved drug other | 8 sections |
| EXODEN ALL IN ONE | HUMAN OTC DRUG LABEL | 4 | 70602-010 | PASTE | 10 g | TOPICAL | unapproved drug other | 8 sections |
| Chunzam Silk Amino Acid Tooth | HUMAN OTC DRUG LABEL | 3 | 71078-0001 | PASTE, DENTIFRICE | 4 g | DENTAL | unapproved drug other | 7 sections |
| Purigo | HUMAN OTC DRUG LABEL | 3 | 71710-0001 | LIQUID | 31 g | TOPICAL | unapproved drug other | 7 sections |
| OPRECARE 12 | HUMAN OTC DRUG LABEL | 1 | 71764-101 | GEL | 1.71 g | DENTAL | unapproved drug other | 8 sections |
| OPRECARE 24 | HUMAN OTC DRUG LABEL | 1 | 71764-103 | GEL | 1.43 g | DENTAL | unapproved drug other | 8 sections |
| LACSIAN new perfect all care tooth | HUMAN OTC DRUG LABEL | 3 | 72048-030 | PASTE, DENTIFRICE | 18 g | TOPICAL | unapproved drug other | 8 sections |
| Dr.Pauhls TOOTHPAST E LIME MANDARIN FLAVOR | HUMAN OTC DRUG LABEL | 2 | 72265-010 | PASTE, DENTIFRICE | 13 g | TOPICAL | unapproved drug other | 8 sections |